Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease.

Crohn’s disease prognosis screening ulcerative colitis

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 11 10 2023
revised: 31 01 2024
accepted: 03 02 2024
medline: 3 3 2024
pubmed: 3 3 2024
entrez: 2 3 2024
Statut: aheadofprint

Résumé

Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their increased risk of colorectal cancer (CRC). We aimed to develop and validate a dynamic prediction model for the occurrence of advanced colorectal neoplasia (aCRN, including high-grade dysplasia and CRC) in IBD. We pooled data from six existing cohort studies from Canada, the Netherlands, the UK, and the USA. Patients with IBD and an indication for CRC surveillance were included if they underwent at least one follow-up procedure. Exclusion criteria included prior aCRN, prior colectomy, or an unclear indication for surveillance. Predictor variables were selected based on literature. A dynamic prediction model was developed using a landmarking approach based on Cox proportional hazard modelling. Model performance was assessed with Harrell's concordance-statistic (discrimination) and by calibration curves. Generalizability across surveillance cohorts was evaluated by internal-external cross-validation. The surveillance cohorts comprised 3,731 patients, enrolled and followed-up in the time period 1973-2021, with a median follow-up of 5.7 years (26,336 patient-years of follow-up); 146 individuals were diagnosed with aCRN. The model contained eight predictors, with a cross-validation median c-statistic of 0.74 and 0.75 for a 5- and 10-year prediction window, respectively. Calibration plots showed good calibration. Internal-external cross-validation results showed medium discrimination and reasonable to good calibration. The new prediction model showed good discrimination and calibration, however, generalizability results varied. Future research should focus on formal external validation and relate predicted aCRN risks to surveillance intervals prior to clinical application.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their increased risk of colorectal cancer (CRC). We aimed to develop and validate a dynamic prediction model for the occurrence of advanced colorectal neoplasia (aCRN, including high-grade dysplasia and CRC) in IBD.
METHODS METHODS
We pooled data from six existing cohort studies from Canada, the Netherlands, the UK, and the USA. Patients with IBD and an indication for CRC surveillance were included if they underwent at least one follow-up procedure. Exclusion criteria included prior aCRN, prior colectomy, or an unclear indication for surveillance. Predictor variables were selected based on literature. A dynamic prediction model was developed using a landmarking approach based on Cox proportional hazard modelling. Model performance was assessed with Harrell's concordance-statistic (discrimination) and by calibration curves. Generalizability across surveillance cohorts was evaluated by internal-external cross-validation.
RESULTS RESULTS
The surveillance cohorts comprised 3,731 patients, enrolled and followed-up in the time period 1973-2021, with a median follow-up of 5.7 years (26,336 patient-years of follow-up); 146 individuals were diagnosed with aCRN. The model contained eight predictors, with a cross-validation median c-statistic of 0.74 and 0.75 for a 5- and 10-year prediction window, respectively. Calibration plots showed good calibration. Internal-external cross-validation results showed medium discrimination and reasonable to good calibration.
CONCLUSION CONCLUSIONS
The new prediction model showed good discrimination and calibration, however, generalizability results varied. Future research should focus on formal external validation and relate predicted aCRN risks to surveillance intervals prior to clinical application.

Identifiants

pubmed: 38431223
pii: S1542-3565(24)00214-3
doi: 10.1016/j.cgh.2024.02.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Adriaan A van Bodegraven (AA)
Herma H Fidder (HH)
Meike M C Hirdes (MMC)
Frank Hoentjen (F)
Jeroen M Jansen (JM)
Nofel Mahmmod (N)
Andrea E van der Meulen-de Jong (AE)
Cyriel Y Ponsioen (CY)
Fiona D M van Schaik (FDM)
C Janneke van der Woude (C)

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Anouk M Wijnands (AM)

Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Bas B L Penning de Vries (BBL)

Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Maurice W M D Lutgens (MWMD)

Department of Gastroenterology and Hepatology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.

Zeinab Bakhshi (Z)

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Rochester, MN, USA.

Ibrahim Al Bakir (I)

Department of gastroenterology, Chelsea and Westminster Hospital, London, UK.

Laurent Beaugerie (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France.

Charles N Bernstein (CN)

University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Ryan Chang-Ho Choi (R)

Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, NSW, Australia.

Nayantara Coelho-Prabhu (N)

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Rochester, MN, USA.

Trevor A Graham (TA)

Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK and Genomics and Evolutionary Dynamics Laboratory, Centre for Evolution and Cancer, Institute of Cancer Research, London, UK.

Ailsa L Hart (AL)

Inflammatory Bowel Disease Unit, St Mark's Hospital, London, UK.

Joren R Ten Hove (JR)

Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Steven H Itzkowitz (SH)

Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.

Julien Kirchgesner (J)

Department of Gastroenterology and Hepatology, Hôpital Saint-Antoine, Paris, France.

Erik Mooiweer (E)

Department of Gastroenterology and Hepatology, Hospital St Jansdal, Harderwijk, The Netherlands.

Seth R Shaffer (SR)

University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Shailja C Shah (SC)

Division of Gastroenterology, University of California San Diego, San Diego, California; GI Section, VA San Diego Healthcare Center, San Diego, California.

Sjoerd G Elias (SG)

Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Bas Oldenburg (B)

Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands. Electronic address: boldenbu@umcutrecht.nl.

Classifications MeSH